Public Summary Document – March 2014 PBAC Meeting 5.8 FLUTICASONE FUROATE AND VILANTEROL TRIFENATATE, fluticasone furoate 100 microgram actuation vilanterol - Azelastine - Document - PDFSEARCH.IO

First Page		Document Content
Date: 2015-03-23 21:11:42 GlaxoSmithKline Glucocorticoids Asthma Organofluorides Fluticasone/salmeterol Salmeterol Formoterol Fluticasone propionate Fluticasone furoate Pulmonology Medicine Respiratory therapy		Public Summary Document – March 2014 PBAC Meeting 5.8 FLUTICASONE FUROATE AND VILANTEROL TRIFENATATE, fluticasone furoate 100 microgram/actuation + vilanterol Add to Reading List Source URL: www.pbs.gov.au Download Document from Source Website File Size: 290,01 KB Share Document on Facebook

	Summary of Steering Committee Conference Call, 28 July 2014 Present: M. Alexander (Diageo); S. Arango (Grupo Nutresa); N. Barak (Netafim); C. Brown (Olam); J. Cassin (Forest Trends); B. Fulford (GlaxoSmithKline); M. Gins DocID: 1sIGp - View Document
	TDR Career Development Fellowship: Clinical Research & Development at GlaxoSmithKline Biologicals DocID: 1s3Bu - View Document
	Harnessing Information for Efficiency and Growth Gary Armstrong, GlaxoSmithKline Organisations and individuals are generating vast amounts of data DocID: 1rEBP - View Document
	GSK-Positionspapier GSK-Positionspapier Zusammenarbeit mit Dritten Zum Thema GlaxoSmithKline (GSK) verpflichtet sich, nach den höchsten ethischen Standards zu arbeiten, um zur langfristigen Nachhaltigkeit unseres Unter DocID: 1ry7L - View Document
	Information, Marketing, and Pricing in the U.S. Antiulcer Drug Market Ernst R. Berndt; Linda Bui; David R. Reiley; Glen L. Urban The American Economic Review, Vol. 85, No. 2, Papers and Proceedings of the Hundredth and S DocID: 1rtYb - View Document